IL275038B2 - Formulation for anti-antibody alpha 4 in cell 7 - Google Patents

Formulation for anti-antibody alpha 4 in cell 7

Info

Publication number
IL275038B2
IL275038B2 IL275038A IL27503820A IL275038B2 IL 275038 B2 IL275038 B2 IL 275038B2 IL 275038 A IL275038 A IL 275038A IL 27503820 A IL27503820 A IL 27503820A IL 275038 B2 IL275038 B2 IL 275038B2
Authority
IL
Israel
Prior art keywords
antibody
seq
set forth
medicament
dose
Prior art date
Application number
IL275038A
Other languages
English (en)
Hebrew (he)
Other versions
IL275038A (en
IL275038B (en
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL275038(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of IL275038A publication Critical patent/IL275038A/en
Publication of IL275038B publication Critical patent/IL275038B/en
Publication of IL275038B2 publication Critical patent/IL275038B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Endocrinology (AREA)
IL275038A 2011-05-02 2012-05-02 Formulation for anti-antibody alpha 4 in cell 7 IL275038B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161481533P 2011-05-02 2011-05-02
US201161550545P 2011-10-24 2011-10-24
US201261585859P 2012-01-12 2012-01-12
PCT/US2012/036072 WO2012151248A2 (en) 2011-05-02 2012-05-02 FORMULATION FOR ANTI-α4β7 ANTIBODY

Publications (3)

Publication Number Publication Date
IL275038A IL275038A (en) 2020-07-30
IL275038B IL275038B (en) 2022-11-01
IL275038B2 true IL275038B2 (en) 2023-03-01

Family

ID=46085207

Family Applications (5)

Application Number Title Priority Date Filing Date
IL296847A IL296847A (en) 2011-05-02 2012-05-02 Formulation for anti-antibody alpha 4 in cell 7
IL275038A IL275038B2 (en) 2011-05-02 2012-05-02 Formulation for anti-antibody alpha 4 in cell 7
IL296838A IL296838A (en) 2011-05-02 2012-05-02 Formulation for anti-antibody alpha 4 in cell 7
IL229104A IL229104A0 (en) 2011-05-02 2013-10-28 Formulation for anti-antibody alpha 4 in cell 7
IL267668A IL267668B (en) 2011-05-02 2019-06-26 Formulation for anti-antibody alpha 4 in cell 7

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL296847A IL296847A (en) 2011-05-02 2012-05-02 Formulation for anti-antibody alpha 4 in cell 7

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL296838A IL296838A (en) 2011-05-02 2012-05-02 Formulation for anti-antibody alpha 4 in cell 7
IL229104A IL229104A0 (en) 2011-05-02 2013-10-28 Formulation for anti-antibody alpha 4 in cell 7
IL267668A IL267668B (en) 2011-05-02 2019-06-26 Formulation for anti-antibody alpha 4 in cell 7

Country Status (42)

Country Link
US (16) US20120282249A1 (enExample)
EP (4) EP2704798B1 (enExample)
JP (7) JP6190360B2 (enExample)
KR (8) KR20220154834A (enExample)
CN (4) CN103608071B (enExample)
AR (1) AR086237A1 (enExample)
AU (7) AU2012250873B2 (enExample)
BR (1) BR112013028424A2 (enExample)
CA (2) CA3028209C (enExample)
CL (2) CL2013003146A1 (enExample)
CO (1) CO6801647A2 (enExample)
CR (1) CR20130677A (enExample)
CY (1) CY1119435T1 (enExample)
DK (2) DK3329965T3 (enExample)
DO (1) DOP2013000253A (enExample)
EA (1) EA032729B1 (enExample)
EC (2) ECSP13013050A (enExample)
ES (2) ES2645187T3 (enExample)
FI (1) FI3329965T3 (enExample)
GE (1) GEP201706734B (enExample)
HK (1) HK1249466A1 (enExample)
HR (2) HRP20171432T1 (enExample)
HU (2) HUE036663T2 (enExample)
IL (5) IL296847A (enExample)
LT (2) LT3329965T (enExample)
MA (1) MA35136B1 (enExample)
ME (1) ME02859B (enExample)
MX (4) MX348814B (enExample)
MY (2) MY172735A (enExample)
PE (2) PE20190405A1 (enExample)
PH (3) PH12018500030B1 (enExample)
PL (2) PL2704798T3 (enExample)
PT (2) PT2704798T (enExample)
RS (2) RS56397B1 (enExample)
SG (1) SG194652A1 (enExample)
SI (2) SI3329965T1 (enExample)
SM (2) SMT201700508T1 (enExample)
TW (3) TWI664978B (enExample)
UA (2) UA116189C2 (enExample)
UY (1) UY34053A (enExample)
WO (1) WO2012151248A2 (enExample)
ZA (3) ZA201308069B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
LT2704742T (lt) 2011-05-02 2017-10-25 Millennium Pharmaceuticals, Inc. Anti-alfa4beta7 antikūno kompozicija
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20140286969A1 (en) * 2013-03-15 2014-09-25 Abbvie Inc. Anti-egfr antibody drug conjugate formulations
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
RU2689145C2 (ru) * 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
MA40592A (fr) 2014-10-06 2016-04-14 Chemocentryx Inc Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US20170360926A1 (en) 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
MX2018001668A (es) * 2015-08-11 2018-05-07 Univ Osaka Anticuerpo.
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
CA3017758A1 (en) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
KR102710759B1 (ko) * 2016-03-14 2024-09-25 밀레니엄 파머슈티컬스 인코퍼레이티드 이식편대숙주 질환을 예방하는 방법
WO2017158393A1 (en) * 2016-03-18 2017-09-21 Oslo University Hospital Hf Methods of treating graft-versus-host disease
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
MA44864A (fr) 2016-05-04 2019-03-13 Icahn School Med Mount Sinai Trithérapie pour le traitement d'une maladie intestinale inflammatoire
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
MY197672A (en) * 2016-10-07 2023-07-03 Regeneron Pharma Room temperature stable lyophilized protein
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
CN110267685B (zh) * 2016-12-23 2023-06-20 伊缪诺金公司 靶向adam9的免疫缀合物及其使用方法
WO2018200818A2 (en) * 2017-04-28 2018-11-01 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
JP7497159B2 (ja) * 2017-05-26 2024-06-10 ミレニアム ファーマシューティカルズ， インコーポレイテッド 慢性回腸嚢炎の治療のための方法
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
IL322968A (en) 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical treatment
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3773696A4 (en) 2018-04-10 2021-12-29 Dr. Reddy's Laboratories Ltd. Stable formulations of therapeutic antibody
AU2019253070A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy's Laboratories Limited Antibody formulation
US12024561B2 (en) * 2018-04-10 2024-07-02 Dr. Reddy's Laboratories Limited Stable antibody formulation
CN118130807A (zh) 2018-05-31 2024-06-04 小野药品工业株式会社 用于确定免疫检查点抑制剂的有效性的生物标志物
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN109239335A (zh) * 2018-09-11 2019-01-18 广州万孚生物技术股份有限公司 联检试纸条及其制备方法
WO2020123241A1 (en) * 2018-12-10 2020-06-18 Clear Creek Bio, Inc. Multiphasic dosing regimens for treating cancer
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
MA55735A (fr) * 2019-04-17 2022-02-23 Millennium Pharm Inc Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23
EP3980466A4 (en) * 2019-06-10 2023-06-07 Takeda Pharmaceutical Company Limited Methods of producing an anti-alpha4beta7 antibody
TW202112819A (zh) * 2019-06-10 2021-04-01 美商千禧製藥公司 用於抗體製備之細胞培養方法及組合物
AU2020290999A1 (en) * 2019-06-10 2022-02-03 Takeda Pharmaceutical Company Limited Antibody purification methods and compositions thereof
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
MX2022009844A (es) 2020-02-18 2022-09-05 Novo Nordisk As Composiciones y usos del peptido similar al glucagon-1 (glp-1).
CN113577281A (zh) * 2020-04-30 2021-11-02 中国科学院分子细胞科学卓越创新中心 调控整合素β亚基的试剂和方法
UY39327A (es) 2020-07-16 2022-02-25 Abbvie Inc Anticuerpos anti- alpha-4-beta-7
US20240100158A1 (en) * 2021-01-20 2024-03-28 Dr. Reddy’S Laboratories Limited Freeze dried antibody formulations and methods thereof
BR112023022811A2 (pt) * 2021-05-07 2024-01-16 Dr Reddys Laboratories Ltd Formulações farmacêuticas de um anticorpo alfa-4-beta-7 de alta concentração e de vedolizumabe de alta concentração, e, métodos para controlar a formação de partículas subvisíveis em um anticorpo alfa-4-beta-7 e de variantes de carga ou agregados ou fragmentação do anticorpo em uma composição de anticorpo alfa-4-beta-7 de alta concentração, para controlar a opalescência em uma composição de anticorpo alfa-4-beta-7 de alta concentração e para preparar uma composição de anticorpo alfa-4-beta-7
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
WO2025133872A1 (en) * 2023-12-19 2025-06-26 Intas Pharmaceuticals Ltd. Method for reducing oxidation levels in vedolizumab during cell culture process
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US774216A (en) 1903-11-19 1904-11-08 Alexander F Ward Machine for pointing and lapping hoops.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
ATE114478T1 (de) 1987-08-11 1994-12-15 Univ Leland Stanford Junior Verfahren zur kontrolle der leukozyten- extravasation.
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
WO1990007321A2 (en) 1988-12-23 1990-07-12 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte receptor homing sequences and their uses
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL113261A (en) 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992015683A1 (en) 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
JPH07506566A (ja) 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
WO1993023526A1 (en) 1992-05-21 1993-11-25 Center For Blood Research, Inc. A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON
WO1994012214A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
AU687790B2 (en) 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
AU703152B2 (en) 1994-01-25 1999-03-18 Biogen Ma Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
KR20040105740A (ko) * 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
EP1507756B1 (en) 2002-05-24 2015-07-22 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
EP1562940B1 (en) 2002-11-18 2007-05-30 ChemoCentryx Inc Aryl sulfonamides
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
EP1784426B1 (en) * 2004-09-03 2011-11-23 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
US20070122404A1 (en) * 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
CN101426817B (zh) 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
US20080112953A1 (en) 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
CA2671968A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
CA2697163A1 (en) * 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
WO2010100200A2 (en) 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
EP2442798A4 (en) * 2009-06-18 2013-03-13 Wyeth Llc LYOPHILIZED FORMULATIONS FOR SMALL-SCALE MODULAR IMMUNOPHARMACEUTICAL AGENTS
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
SG193565A1 (en) 2011-03-31 2013-11-29 Genentech Inc Methods of administering beta7 integrin antagonists
LT2704742T (lt) 2011-05-02 2017-10-25 Millennium Pharmaceuticals, Inc. Anti-alfa4beta7 antikūno kompozicija
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en) * 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US20170360926A1 (en) 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
MA44864A (fr) 2016-05-04 2019-03-13 Icahn School Med Mount Sinai Trithérapie pour le traitement d'une maladie intestinale inflammatoire
WO2017218434A1 (en) * 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEAGAN, BRIAN G., ET AL., TREATMENT OF ULCERATIVE COLITIS WITH A HUMANIZED ANTIBODY TO THE ?4?7 INTEGRIN., 16 June 2005 (2005-06-16) *

Also Published As

Publication number Publication date
AU2020250249A1 (en) 2020-11-05
IL267668A (en) 2019-08-29
US20250295786A1 (en) 2025-09-25
PL3329965T3 (pl) 2025-04-28
EP4378484A2 (en) 2024-06-05
SMT202500218T1 (it) 2025-07-22
US20180207279A1 (en) 2018-07-26
GEP201706734B (en) 2017-09-25
KR20180050435A (ko) 2018-05-14
SMT201700508T1 (it) 2017-11-15
EP2704798B1 (en) 2017-07-12
CA2834867C (en) 2019-02-12
EP3263178A1 (en) 2018-01-03
CN108079291A (zh) 2018-05-29
CN103608071A (zh) 2014-02-26
AR086237A1 (es) 2013-11-27
CY1119435T1 (el) 2018-03-07
IL267668B (en) 2020-10-29
JP6190360B2 (ja) 2017-08-30
CA3028209A1 (en) 2012-11-08
WO2012151248A3 (en) 2013-02-28
UA116189C2 (uk) 2018-02-26
ME02859B (me) 2018-04-20
MX356827B (es) 2018-06-15
HUE036663T2 (hu) 2018-07-30
ZA201308069B (en) 2016-01-27
TWI664978B (zh) 2019-07-11
ES3016382T3 (en) 2025-05-09
DOP2013000253A (es) 2013-12-31
UY34053A (es) 2012-11-30
JP2023076616A (ja) 2023-06-01
PT2704798T (pt) 2017-11-14
US20190231878A1 (en) 2019-08-01
PE20190405A1 (es) 2019-03-14
EP3329965A1 (en) 2018-06-06
MY183471A (en) 2021-02-19
IL229104A0 (en) 2013-12-31
MX2021006723A (es) 2022-05-03
TWI664980B (zh) 2019-07-11
AU2016231469A1 (en) 2016-10-06
TW201906631A (zh) 2019-02-16
UA126545C2 (uk) 2022-11-02
JP7258941B2 (ja) 2023-04-17
LT2704798T (lt) 2017-10-25
US9663579B2 (en) 2017-05-30
CN108129565B (zh) 2022-09-20
US20210052733A1 (en) 2021-02-25
US10004808B2 (en) 2018-06-26
KR20180127540A (ko) 2018-11-28
TWI556828B (zh) 2016-11-11
KR101923378B1 (ko) 2018-11-29
KR20220154834A (ko) 2022-11-22
EP3329965A3 (en) 2018-12-12
ECSP13013050A (es) 2014-01-31
US20120282249A1 (en) 2012-11-08
US20200206353A1 (en) 2020-07-02
IL275038A (en) 2020-07-30
JP6878489B2 (ja) 2021-05-26
ES2645187T3 (es) 2017-12-04
MX2013012724A (es) 2013-12-06
AU2012250873B2 (en) 2016-07-07
AU2019201926A1 (en) 2019-04-11
CN108187042A (zh) 2018-06-22
CO6801647A2 (es) 2013-11-29
US20250288679A1 (en) 2025-09-18
EA032729B1 (ru) 2019-07-31
JP6534415B2 (ja) 2019-06-26
ZA201806946B (en) 2022-03-30
SI2704798T1 (sl) 2017-12-29
PH12020500336A1 (en) 2021-02-22
ECSP22034515A (es) 2022-05-31
KR20140145953A (ko) 2014-12-24
US20250041424A1 (en) 2025-02-06
CA3028209C (en) 2021-01-05
SI3329965T1 (sl) 2025-07-31
PL2704798T3 (pl) 2017-12-29
BR112013028424A2 (pt) 2021-05-04
US20190076532A1 (en) 2019-03-14
AU2020250249B2 (en) 2022-10-06
KR20250094743A (ko) 2025-06-25
KR20210084711A (ko) 2021-07-07
LT3329965T (lt) 2025-06-10
PH12013502236A1 (en) 2014-01-06
PT3329965T (pt) 2025-04-02
KR102275603B1 (ko) 2021-07-08
AU2018278866A1 (en) 2019-01-03
KR101923371B1 (ko) 2018-11-29
US20220370617A1 (en) 2022-11-24
NZ617833A (en) 2016-04-29
US12053526B2 (en) 2024-08-06
JP6473845B2 (ja) 2019-02-20
CR20130677A (es) 2014-10-07
CL2013003146A1 (es) 2014-07-25
KR20170116217A (ko) 2017-10-18
AU2012250873A1 (en) 2013-05-09
MY172735A (en) 2019-12-11
JP2017137351A (ja) 2017-08-10
US9764033B2 (en) 2017-09-19
AU2022231726B2 (en) 2025-01-09
EP3329965B1 (en) 2025-03-19
AU2022231726A1 (en) 2022-10-06
SG194652A1 (en) 2013-12-30
US20180289811A1 (en) 2018-10-11
RS66809B1 (sr) 2025-06-30
PH12018500030A1 (en) 2018-10-15
KR102465394B1 (ko) 2022-11-09
KR102096484B1 (ko) 2020-04-02
IL296838A (en) 2022-11-01
FI3329965T3 (fi) 2025-04-30
HRP20171432T1 (hr) 2017-11-03
CN103608071B (zh) 2017-12-26
US20160340432A1 (en) 2016-11-24
PH12018500030B1 (en) 2022-05-04
TW201718012A (zh) 2017-06-01
CL2017000830A1 (es) 2017-12-22
IL275038B (en) 2022-11-01
CA2834867A1 (en) 2012-11-08
AU2018278866B2 (en) 2020-07-09
IL296847A (en) 2022-11-01
KR20200035503A (ko) 2020-04-03
PE20141175A1 (es) 2014-09-25
EP2704798A2 (en) 2014-03-12
US20160340431A1 (en) 2016-11-24
WO2012151248A2 (en) 2012-11-08
MX348814B (es) 2017-06-30
RS56397B1 (sr) 2017-12-29
DK3329965T3 (da) 2025-04-07
US10143752B2 (en) 2018-12-04
JP7492057B2 (ja) 2024-05-28
US20250000981A1 (en) 2025-01-02
HK1256106A1 (en) 2019-09-13
MA35136B1 (fr) 2014-05-02
JP2024098027A (ja) 2024-07-19
US20140377251A1 (en) 2014-12-25
EP4378484A3 (en) 2024-09-04
AU2025202434A1 (en) 2025-04-24
AU2016231469B2 (en) 2018-12-20
TW201247223A (en) 2012-12-01
DK2704798T3 (en) 2017-10-23
MX383317B (es) 2025-03-13
JP2014514346A (ja) 2014-06-19
CN108129565A (zh) 2018-06-08
US12171832B2 (en) 2024-12-24
HUE071510T2 (hu) 2025-09-28
HK1249466A1 (en) 2018-11-02
US20170002078A1 (en) 2017-01-05
ZA201707158B (en) 2019-01-30
JP2019108400A (ja) 2019-07-04
JP2021113223A (ja) 2021-08-05
CN108079291B (zh) 2022-04-08
EA201391614A1 (ru) 2014-07-30
JP2018150388A (ja) 2018-09-27
HRP20250472T1 (hr) 2025-06-06

Similar Documents

Publication Publication Date Title
US20250295786A1 (en) Methods for treatment using anti-alpha4beta7 antibody
US20230312727A1 (en) Formulation for anti-alpha4beta7 antibody
HK40111834A (en) Formulation for anti-alpha4beta7 antibody
HK1256106B (en) Dosing regimen of anti-alpha4beta7-antibody
NZ617340B2 (en) Formulation for anti-?4?7 antibody
HK1195276B (en) Formulation for anti- alpha4beta7 antibody
HK1195276A (en) Formulation for anti- alpha4beta7 antibody
NZ617833B2 (en) Formulation for anti-?4?7 antibody